Recent developments and advances of FGFR as a potential target in cancer. (1st August 2018)

• Record Type: Journal Article
• Authors: Xue, Wen-Jun; Li, Ming-Tao; Chen, Lin; Sun, Li-Ping; Li, Yu-Yan
• Is Part Of: Future medicinal chemistry. Volume 10:Number 17(2018)
• Page Start: 2109
• Page End: 2126
• Publication Date: 2018-08-01
• Subjects: cancer -- FGF/FGFR signaling -- FGF ligand -- FGFR -- FGFR inhibitors -- target; Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.4155/fmc-2018-0103
• Languages: English
• ISSNs: 1756-8919

Abstract

FGFs and their receptors (FGFRs) are critical for many biologic processes, including angiogenesis, wound healing and tissue regeneration. Aberrations in FGFR signaling are common in cancer, making FGFRs a promising target in antitumor studies. To date, many FGFR inhibitors are being detected in clinical studies, and resistance to some inhibitors has emerged. Understanding the mechanisms of resistance is a fundamental step for further implementation of targeted therapies. In this review, we will describe the basic knowledge regarding FGF/FGFR signaling and categorize the clinical FGFR inhibitors. The mechanisms of resistance to FGFR inhibitors and corresponding strategies of overcoming drug resistance will also be discussed.